| Previous Close | 34.34 |
| 1-Year Change | -29.25% |
| 6-Months Change | -7.96% |
| 3-Months Change | -27.92% |
| Moving Avg (50d) | 39.618 |
| Moving Avg (200d) | 43.2 |
| ESG Rating | - |
| Exchange | NASDAQ |
| Market Cap. | 4.92B |
| Beta (3-Years) | 0.8 |
| Revenue Growth (ttm) | -29.75% |
| Net Profit Margin (ttm) | -66.57% |
| Return On Assets (ttm) | -13.96% |
| EPS (ttm) | -2.87 |
| PE Ratio (ttm) | -11.97 |
| Dividend Yield | % |
Glossary:
- TTM: Trailing Twelve Months
- ESG: Environmental, Social and Governance
- EPS: Earnings Per Share
Summary of the Company's Financials
- The company Fiscal Period is usually around December 31, each year.
- The latest company financial statement is: 10-Q filed as of 11/02/2023. Link to the latest 10-Q.
- Link to company's latest filings (source data):
The prediction for the asset IONS is not available at the time requested.
The forecast above is based on the AI algorithm ML.
Check the forecast for others algorithms below.
Profitability ratios measure a company’s ability to generate income relative to revenue, balance sheet assets, operating costs, and equity. Common profitability financial ratios include the following.
Profitability Ratios
Liquidity ratios are financial ratios that measure a company’s ability to repay both short- and long-term obligations. Common profitability financial ratios include the following.
Liquidity Ratios
Leverage ratios measure the amount of capital that comes from debt. In other words, leverage financial ratios are used to evaluate a company’s debt levels. Common leverage ratios include the following.
Leverage Ratios
Market value ratios are used to evaluate the share price of a company’s stock. Common market value ratios include the following
Market value ratios
Efficiency ratios are used to measure how well a company is utilizing its assets and resources. Common efficiency ratios include
Efficiency ratios
In Millions USD (except per share data; shares in Millions)
In Millions USD (except per share data; shares in Millions)
In Millions USD (except per share data; shares in Millions)
Statements
- Data are sourced from company financial statements 10-K,10-Q filed with U.S. Securities and Exchange Commission (SEC).
- Some variables might not be found in the statements filed by the company. These are simply deduced from other variables when possible. The dot "." in front of some rows means the variable is not directly found in the statement and thus is deduced from other variables.
- Check Ionis Pharmaceuticals, Inc. financial statements for more details following the link below.
Latest news on Ionis Pharmaceuticals, Inc. are available by following this link.
News feed will be added in the future. Please get in touch with us if you are a news feed provider.
Ask ChatGPT ?
Get financial insights from latest company's financial statements
×
You should login first to use this service
|
Login Here
This might take more than 30s in the first call...
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Want to know about our in-house AI models ?
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Company Profile
Ionis Pharmaceuticals, Inc.
| Sector: | Health Care |
| Industry: | Biotechnology |
| Country: | United States |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx... Wikipedia